Targovax ASA: Invitation to fourth quarter and full year 2016 results presentation Thursday 16 February
(Thomson Reuters ONE) -
Oslo, Norway, 6 February 2017 - Targovax ASA (OSE: TRVX), a clinical stage
company focused on developing immuno-oncology therapies to target solid tumors,
will announce its fourth quarter and full year 2016 results on Thursday, 16
February 2017. A presentation by Targovax's management to investors, analysts
and the press will take place in Oslo at 10:00 CET.
The results report and the presentation will be available at www.targovax.com in
the Investors section from 07:00 CET.
Presentation
The presentation will take place at 10:00 CET at:
Hotel Continental
Stortingsgaten 24/26
0117 Oslo
The presentation will also be webcast live and can be accessed through
www.targovax.com.
Conference call
At 14:00 CET (08:00 EST) The company will host a telephone conference which will
include a presentation of the results, following a Q&A session. CEO Øystein Soug
will present the company. Call in details can be found below.
Call-in numbers:
Norway Toll-Free Number: 800 19 747
Norway Toll Number: +472350 0559
UK Toll-Free Number: 08082370030
UK Toll Number: +442031394830
US Toll-Free Number: 1866 928 7517
US Toll Number: +1 718 873 9077
Access code: 54717166#
Please make sure to dial in at least 5-10 minutes ahead to complete your
registration.
See attached list for more dial-in numbers.
http://events.arkadin.com/ev/docs/NE_FEL_Events_International_Access_List.pdf
--------------------------------------------------------------------------------
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli(at)targovax.com
Media and IR enquires:
Jan Petter Stiff - Crux Advisers (Norway)
Phone: +47 995 13 891
Email: stiff(at)crux.no
Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax(at)fticonsulting.com
About Targovax
Arming the patient's immune system to fight cancer
Targovax is a clinical stage company focused on developing novel immuno-oncology
therapies to target, primarily, treatment-resistant solid tumors. Immuno-
oncology is currently one of the fastest growing therapeutic fields in medicine.
The Company's development pipeline has arisen from two novel proprietary
platforms:
The first platform, ONCOS, uses oncolytic viruses, an emerging class of
biological therapy. ONCOS exclusively uses an adenovirus that has been
engineered to be a tumor-targeted immune activator. The platform has the
potential to generate therapies with superior efficacy and safety compared to
the first approved oncolytic virus therapy, Imlygic, recently launched by Amgen.
We expect proof of concept data related to immune activation in tumor tissue in
2017 from the clinical trial of ONCOS-102 in combination wih CPI in patients
with refractory malignant melanoma.
The second platform, TG-Peptides, solely targets tumors that express mutated
forms of the RAS protein. Mutations to this protein are common in many cancers
and are known to drive aggressive disease progression and treatment resistance.
There is a high unmet medical need for therapies that are effective against
tumors that express these mutations. The TG platform's therapeutic potential
stems from its ability to enable a patient's immune system to identify and then
destroy tumors bearing any RAS mutations.
The development pipeline has three novel therapeutic candidates in clinical
development covering six indications and has already demonstrated promising
safety and tolerability data and early signs of clinical response.
Both platforms are protected by an extensive portfolio of IP and know-how and
have the potential to yield multiple product candidates in a cost effective
manner. Our portfolio of future opportunities comprises a number of early stage
development candidates in addition to the three outlined above.
In July 2016 the Company listed its shares on Oslo Axess, securing funding for
further development of the Company's ongoing and planned trials.
This information is subject to the disclosure requirements pursuant to section
5 -12 of the Norwegian Securities Trading Act.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 06.02.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 522013
Anzahl Zeichen: 5188
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 258 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax ASA: Invitation to fourth quarter and full year 2016 results presentation Thursday 16 February"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
